Relevant bibliographies by topics / Pharmaceutical producers

Academic literature on the topic 'Pharmaceutical producers'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical producers.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical producers"

1

Sridharan, Perumal. "Multinational Diversification and Pharmaceutical Units Performance: Evidence from Indian Firms." Ushus - Journal of Business Management 12, no. 3 (July 7, 2013): 77–87. http://dx.doi.org/10.12725/ujbm.24.5.

Full text
Abstract:
This paper examines the performance of select Foreign Direct Invested (FDI) assisted pharmaceutical units in India for the period from 1st April 1999 to 31st March 2008. The dataset has been retrieved from CMIE Prowess database and Organization of Pharmaceuticals Producers of India (OPPI) for 23 FDI assisted pharmaceutical units and evaluated through
APA, Harvard, Vancouver, ISO, and other styles
2

Mance, Davor, Nenad Vretenar, and Antonija Gudelj. "Mergers and Acquisitions as a Consequence of Declining Innovation Productivity in Pharmaceuticals: Evidence from Croatia." Mednarodno inovativno poslovanje = Journal of Innovative Business and Management 12, no. 1 (June 30, 2020): 1–8. http://dx.doi.org/10.32015/jibm/2020-12-1-1.

Full text
Abstract:
Declining productivity of pharmaceutical innovation resulted in an increased number of mergers & acquisitions in the pharmaceutical industry. Increased investments into research & development lack the resulting increases in patentable new substances. As a result, the once market leaders are not buying their followers, but the generics producers are buying unsuccessful innovators. We show the case of Pliva: once regional pharma leader that declined into a generics producer's subsidiary. The Pliva sought new ideas by acquiring several research centres. After these acquisitions produced no visible results, the company itself was a target, first by another unsuccessful R&D based company and lastly, by a successful generics producer.
APA, Harvard, Vancouver, ISO, and other styles
3

Iyengar, Renganthan. "PHARMACEUTICAL PRICING POLICY AND CONTROL– INDIAN PERSPECTIVE." Asian Journal of Pharmaceutical and Clinical Research 9, no. 6 (November 1, 2016): 305. http://dx.doi.org/10.22159/ajpcr.2016.v9i6.14461.

Full text
Abstract:
ABSTRACTPharmaceutical sector is playing a vital role towards the wellness of the people and economic development of India. The innovation, development, production and marketing of medicines are accountable to pharmaceutical industry. Drugs and pharmaceuticals, healthcare delivery, medical devices among others come under the purview of healthcare sector. It is the duty of the Government to ensure the availability of the lifesaving drugs at reasonable prices by means of considering the interest of both the producers and the buyers. In order to safeguard the public health, National Pharmaceutical Pricing Authority (NPPA) is the watchdog in India, which controls the prices of drugs.Keywords: Pharmaceutical sector, Price, Drugs, Regulator,NPPA,DPCO
APA, Harvard, Vancouver, ISO, and other styles
4

Derenska, Yana. "Approaches to project portfolio formation by pharmaceutical products producers." Economic Annals-ХХI 176, no. 3-4 (August 20, 2019): 99–108. http://dx.doi.org/10.21003/ea.v176-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mamedyarov, Z. A. "Pharmaceutical Industry Development in the Midst of Crisis: Global Trends." MIR (Modernization. Innovation. Research) 11, no. 4 (December 28, 2020): 398–408. http://dx.doi.org/10.18184/2079-4665.2020.11.4.398-408.

Full text
Abstract:
Purpose: the main purpose of the article was to study the trends in the global pharmaceutical industry, as one of the most knowledge-intensive in the world economy, against the background of the 2020 COVID-related crisis. The task was to study the impact of the economic crisis on the priorities of the largest pharmaceutical multinationals, to link them with trends in the restructuring of health care systems, as well as to analyze and assess the potential impact of Brexit on the European pharma industry, starting from 2021.Methods: the work is based on a comparative analysis of trends in the restructuring of global value chains in pharmaceuticals, the digitalization of pharmaceuticals and health care, as well as a quantitative analysis of the revenue and value added by the largest European pharmaceutical multinational companies.Results: the COVID-19 pandemic has accelerated the process of digitalization of big pharma; the intensified transition to a continuous production model can be expected in the coming years. Also, the second largest industry market, the EU-27, will suffer less from Brexit than the UK itself, and industries in developing countries will benefit from additional growth opportunities. The digitalization of healthcare remains an important underlying factor for the transformation of pharmaceuticals and further growth of innovation competition. This paper presents the problems of pharma and how to address them, as well as possible ways to restructure healthcare systems to reduce the likelihood of new pandemics – this will be at the heart of regulatory solutions in the medium term.Conclusions and Relevance: governments and state regulators will be actively involved in the process of recovery of the pharmaceutical industry after the crisis. For small regional pharmaceutical producers in developing countries there is a growing need to digitalize production and diversify supply chains. Implementation of continuous production technologies allows expecting growth in the number of small pharmaceutical producers, deepening competition in the industry. The Brexit deal will also have significant implications for the industry, leading to a restructuring of supply chains within the EU from early 2021, reducing the UK's competitiveness.
APA, Harvard, Vancouver, ISO, and other styles
6

Curti, Andrea M. "The WTO Dispute Settlement Understanding: An Unlikely Weapon in the Fight Against AIDS." American Journal of Law & Medicine 27, no. 4 (2001): 469–85. http://dx.doi.org/10.1017/s0098858800008224.

Full text
Abstract:
One of the most controversial aspects of the World Trade Organization (WTO) is its trade policy governing pharmaceutical products that treat AIDS and other diseases. Critics contend that the WTO unreasonably restricts the trade of pharmaceuticals in order to protect the profit margin of western drug producers at the expense of infected populations in developing countries. Supporters of the WTO's trade policy argue that protecting the intellectual property (IP) rights of pharmaceutical products is essential to providing an incentive for further drug research and development.
APA, Harvard, Vancouver, ISO, and other styles
7

Zhou, Lilong, Chen Ma, Jonathan Horlyck, Runjing Liu, and Jimmy Yun. "Development of Pharmaceutical VOCs Elimination by Catalytic Processes in China." Catalysts 10, no. 6 (June 13, 2020): 668. http://dx.doi.org/10.3390/catal10060668.

Full text
Abstract:
As a byproduct of emerging as one of the world’s key producers of pharmaceuticals, China is now challenged by the emission of harmful pharmaceutical VOCs. In this review, the catalogue and volume of VOCs emitted by the pharmaceutical industry in China was introduced. The commonly used VOC removal processes and technologies was recommended by some typical examples. The progress of catalytic combustion, photocatalytic oxidation, non-thermal plasma, and electron beam treatment were presented, especially the development of catalysts. The advantages and shortages of these technologies in recent years were discussed and analyzed. Lastly, the development of VOCs elimination technologies and the most promising technology were discussed.
APA, Harvard, Vancouver, ISO, and other styles
8

Hondius, Ewoud H. "A Dutch DES case: Pharmaceutical Producers Jointly and Severally Liable." European Review of Private Law 2, Issue 3/4 (December 1, 1994): 409–13. http://dx.doi.org/10.54648/erpl1994044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kokkini, Maria, Cristina González Heredia, Daniel Oves-Costales, Mercedes de la Cruz, Pilar Sánchez, Jesús Martín, Francisca Vicente, Olga Genilloud, and Fernando Reyes. "Exploring Micromonospora as Phocoenamicins Producers." Marine Drugs 20, no. 12 (December 7, 2022): 769. http://dx.doi.org/10.3390/md20120769.

Full text
Abstract:
Over the past few years, new technological and scientific advances have reinforced the field of natural product discovery. The spirotetronate class of natural products has recently grown with the discovery of phocoenamicins, natural actinomycete derived compounds that possess different antibiotic activities. Exploring the MEDINA’s strain collection, 27 actinomycete strains, including three marine-derived and 24 terrestrial strains, were identified as possible phocoenamicins producers and their taxonomic identification by 16S rDNA sequencing showed that they all belong to the Micromonospora genus. Using an OSMAC approach, all the strains were cultivated in 10 different media each, resulting in 270 fermentations, whose extracts were analyzed by LC-HRMS and subjected to High-throughput screening (HTS) against methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium tuberculosis H37Ra and Mycobacterium bovis. The combination of LC-UV-HRMS analyses, metabolomics analysis and molecular networking (GNPS) revealed that they produce several related spirotetronates not disclosed before. Variations in the culture media were identified as the most determining factor for phocoenamicin production and the best producer strains and media were established. Herein, we reported the chemically diverse production and metabolic profiling of Micromonospora sp. strains, including the known phocoenamicins and maklamicin, reported for the first time as being related to this family of compounds, as well as the bioactivity of their crude extracts. Although our findings do not confirm previous statements about phocoenamicins production only in unique marine environments, they have identified marine-derived Micromonospora species as the best producers of phocoenamicins in terms of both the abundance in their extracts of some major members of the structural class and the variety of molecular structures produced.
APA, Harvard, Vancouver, ISO, and other styles
10

Sadek, Md Abu Zafor. "Pharmaceutical Plastic Packaging Market in Bangladesh: A Study on Demand-Supply Scenario and Strategic Imperatives for Local Enterprises." International Journal of Business and Management 12, no. 3 (February 21, 2017): 232. http://dx.doi.org/10.5539/ijbm.v12n3p232.

Full text
Abstract:
Pharmaceutical packaging is highly sophisticated industry as quality and safety issues are of utmost priority. Use of advanced technology and high grade plastic materials for pharmaceutical packaging is essence of the market success. In Bangladesh, 30 local pharmaceuticals plastic packaging material producers are capturing almost 70% of the local market while the rest (30%) that require extremely high-tech processing is import dependent. Nevertheless, some local plastic companies are setting up world-class dedicated plant for pharmaceutical plastic packaging, while some pharmaceutical companies such as Square and Acme are extending their facility into backward value segment of the plastic packaging industry. This study strives to determine the market size, major players of the industry–both from supply and demand sides–along with individual contribution in terms of value. It also outlines strategic imperatives for growth and competitiveness of the enterprises involved in the industry.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical producers"

1

Alev, Isil. "Operational perspectives on extended producer responsibility for durable and consumable products." Diss., Georgia Institute of Technology, 2015. http://hdl.handle.net/1853/54382.

Full text
Abstract:
This thesis consists of three essays that contribute to the understanding of the economic implications of Extended Producer Responsibility (EPR) for certain durable (e.g. electronics) and consumable (e.g. pharmaceuticals) products from an operational perspective. In the first essay, we investigate the effect of EPR-based policy on a durable good producer’s secondary market strategy. Our analysis uncovers possible strategic approach of durable good producers to EPR obligations, which may result in unintended outcomes. We provide insights into how to set EPR obligations to avoid these adverse outcomes. In the second essay, we examine the operational details of market-based EPR implementation on the ground. We analyze whether the advocated premises of the marked-based approach hold by focusing on the Minnesota Electronics Recycling Act. Based on evaluation reports and stakeholder interviews, we find that the Minnesota Act achieves the premises of the market-based approach, but this occurs at the expense of several unintended outcomes, following unforeseen market dynamics and associated stakeholder interactions. In the third essay, we explore how the EPR-based policies can be effectively operationalized for managing pharmaceutical overage by analyzing the interactions between major stakeholders and moderating factors for these interactions. We demonstrate that the preferred policy depends on the healthcare and externality characteristics of the medicine together with collection-related requirements. Additionally, we investigate the perspectives of pharmaceutical stakeholders on the policy choice and identify the influential factors in this context.
APA, Harvard, Vancouver, ISO, and other styles
2

Oliva, Viera Ivette Lorena. "Factores que determinaron el incremento de las importaciones de los productos farmacéuticos chinos en el Perú, entre el 2013 al 2017." Bachelor's thesis, Universidad Peruana de Ciencias Aplicadas (UPC), 2019. http://hdl.handle.net/10757/628116.

Full text
Abstract:
La presente investigación tiene como objetivo determinar aquellos factores que generaron el incremento de las importaciones de los productos farmacéuticos chinos en el Perú, entre los años 2013 al 2017. En principio, se analizaron las fuentes secundarias de la industria farmacéutica y las teorías de aplicación para entender mejor la industria y conocer los factores más relevantes que están impulsando el incremento de dichas importaciones chinas, sobre todo por tener un impacto directo con la salud y el bienestar de las personas. De acuerdo a la investigación exhaustiva en el marco teórico, se determinó que el capital y la mano de obra, diversificación, los costos logísticos, el régimen de políticas y la capacidad industrial, son factores determinantes que contribuyen al incremento de las importaciones de los productos farmacéuticos chinos en el Perú. En tanto, la metodología de trabajo aplicada corresponde a un estudio de tipo cualitativo – descriptivo, con diseño no experimental y que utiliza como instrumento de investigación a la entrevista en profundidad, cuyo resultado demostró que cuatro de los cinco factores son considerados determinantes con relación a nuestro tema de estudio. Es decir, el factor de la diversificación no fue considerado determinante para el presente tema de estudio. Debido a la investigación, se recomienda que la industria farmacéutica nacional y privada realice mejores prácticas empresariales con respecto a la utilización de estos factores de modo que puedan no sólo emular lo hecho por China, sino lograr elevar su competitividad en el mercado peruano hacia una industria farmacéutica más fortalecida.
This research aims to determine those factors that generated the increase in imports of Chinese pharmaceutical products in Peru, between 2013 and 2017. In principle, secondary sources of the pharmaceutical industry and application theories were analyzed to better understand the industry and to know the most relevant factors that are driving the increase in these Chinese imports, especially for having a direct impact on health and health. people's well-being According to the exhaustive research in the theoretical framework, it was determined that capital and labor, diversification, logistics costs, policy regime and industrial capacity are determining factors that contribute to the increase in product imports. Chinese pharmacists in Peru. Meanwhile, the applied work methodology corresponds to a qualitative - descriptive study, with a non-experimental design and that uses the in-depth interview as a research instrument, the result of which showed that four of the five factors are considered determinants in relation to Our subject of study. That is, the diversification factor was not considered decisive for the present subject of study. Due to the research, it is recommended that the national and private pharmaceutical industry make better business practices regarding the use of these factors so that they can not only emulate what China has done, but also increase their competitiveness in the Peruvian market towards an industry most strengthened pharmaceutical.
Tesis
APA, Harvard, Vancouver, ISO, and other styles
3

Adolfsson, Per. "Export of Pharmaceutical Products : An analysis of which factors that affects Sweden’s export of pharmaceutical products." Thesis, Jönköping University, JIBS, Economics, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-951.

Full text
Abstract:

The pharmaceutical industry is one of Sweden’s most important export industries with 6% of total exports. The purpose of this thesis is to analyse which factors affect Sweden’s ex-port of pharmaceutical products. Further, the different pharmaceutical products group Sweden exports will be identified. The modern trade theory, the monopolistic competition model, the product life cycle theory and the gravity equation are used to explain and to un-derstand the problem at hand.

To analyse the problem, data of Swedish export of pharmaceutical products from 1997 to 2003 was used to the 176 destination countries Sweden exported to during the time period. The following factors were used as independent variables; distance, Gross Domestic Prod-uct (GDP) /capita, Area, Population, dummy variable for EU-membership, dummy vari-able for English or Scandinavian speaking countries, dummy variable for bordering to Sweden, dummy variable for same religion as Sweden and a dummy variable for countries that are not land-locked.

The findings coincide with previous studies in the manner that distance and GDP/capita have a major impact on the sales abroad of pharmaceutical products. Also, countries with a larger population are importing more than countries with a smaller population. However, the strong affinities between the exporter and the importing countries found in previous studies were not found in the export of pharmaceutical products. Further, Sweden exports most of the product group that includes medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses.


Läkemedelsindustrin är en av Sveriges viktigaste exportindustrier med 6 % av den totala exporten. Syftet med denna uppsats är därför att analysera vilka faktorer som påverkar dess export. Vidare, de olika exportgrupperna av läkemedel som Sverige exporterar kommer att identifieras. Den moderna handelsteorin, monopolistisk konkurrens, produktcykelteorin och gravitationsmodellen används för att förklara och förstå det uppstådda problemet.

För att analysera problemet så används Sveriges export av läkemedel från 1997 till 2003 för alla 176 destinationer. Följande faktorer används som oberoende variabler; distansen, BNP/capita, arean, folkmängd, dummy variabel för EU-medlemskap, dummy variabel för engelsk- eller skandinaviskspråkiga länder, dummy variabel för gränsande länder till Sverige, dummy variabel för länder som har samma religion som Sverige, samt en dummy variabel för länder som angränsar till vatten.

Resultatet överensstämmer med tidigare forskning att avståndet och BNP/capita har ett stort inflytande av exporten av läkemedel. Likaså länder med ett stort invånarantal importe-rar mer än länder med ett mindre invånarantal. Däremot, det starka släktskapet mellan ex-portören och de importerande länderna som funnits i tidigare studier observerades inte i exporten av läkemedel. Vidare, Sverige exporterar mest av produktgruppen som innehåller medikamenter bestående av blandade eller oblandade produkter för terapeutiskt eller profy-laktiskt bruk.

APA, Harvard, Vancouver, ISO, and other styles
4

Komak, Wagma, Jeremy Smart, and Jennifer White. "Quality Assessment of Internet Pharmaceutical Products." The University of Arizona, 2007. http://hdl.handle.net/10150/624403.

Full text
Abstract:
Class of 2007 Abstract
Objectives: The purpose of this study is to assess the quality of study medications obtained without a prescription through international websites. Methods: Samples of levothyroxine, warfarin, and sildenafil were obtained through various websites and compared to U.S. standards. Each sample was physically evaluated for weight, color, shape, and external tablet markings. High performance liquid chromatography (HPLC) was performed to quantify the amount of active ingredient. Results: When physically inspected, only 3 of the 9 lots met FDA labeling requirements. Three of 60 (20 tablets from 3 lots) of the individual levothyroxine tablets were out of the USP acceptable range (90% - 110%). For warfarin, 16 of the 60 samples (20 samples from 3 lots) of the individual tablets were out of the USP acceptable range (95% - 105%). When averaged, each of the lots for both levothyroxine and warfarin were within their USP acceptable ranges. As sildenafil is not available as generic in the U.S., there is no USP standard acceptable range for comparison. All of the sildenafil samples fell within 90%- 105% of Viagra® tablets obtained from a local pharmacy. Conclusions: While there were a few samples outside of the U.S. acceptable range, the majority of samples analyzed for active ingredient were within the range published in the USP. While the outcomes of this study presented interesting findings, further evaluation in larger studies is needed to properly assess the quality of foreign medications purchased over the internet.
APA, Harvard, Vancouver, ISO, and other styles
5

Sadeghnejad, G. R. "Thermoodynamic properties and characterisation of pharmaceutical materials." Thesis, University of Bradford, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.371530.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Östlund, Martin. "AssistancePlus : 3D-mediated Advice-giving on Pharmaceutical Products." Licentiate thesis, Linköping University, Linköping University, NLPLAB - Natural Language Processing Laboratory, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-12159.

Full text
Abstract:

In the use of medication and pharmaceutical products, non‐compliance is a major problem. One thing we can do something about is making sure consumers have the information they need. This thesis investigates how remote communication technology can be used to improve the availability for expressive advice‐giving services. Special attention is given to the balancing of expressiveness and availability. A solution is presented that uses 3D visualisation in combination with audio and video communication to convey advice on complex pharmaceutical products. The solution is tested and evaluated in two user studies. The first study is broad and explorative, the second more focused and evaluative. The solution was well received by participating subjects. They welcomed the sense of personal contact that seeing the communicating party over video link produced and appreciated the expressive power and pedagogical value of the 3D materials. Herbert Clark’s theory of use of language is suggested as a framework for the analysis of the dynamics of the relationship between

consumer and advisor.


Report code: LiU-Tek-Lic-2008:31.
APA, Harvard, Vancouver, ISO, and other styles
7

Östlund, Martin. "AssistancePlus : 3D-mediated advice-giving on pharmaceutical products /." Linköping : Department of Computer and Information Science, Linköpings universitet, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-12159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bara, Carlos Roberto Francisco. "Does humor work in advertising of pharmaceutical products?" reponame:Repositório Institucional do FGV, 2010. http://hdl.handle.net/10438/8196.

Full text
Abstract:
Submitted by Cristiane Shirayama (cristiane.shirayama@fgv.br) on 2011-05-25T16:43:12Z No. of bitstreams: 1 61090100017.pdf: 1173276 bytes, checksum: cda7eb208e82169a3eb90adf64163258 (MD5)
Approved for entry into archive by Vera Lúcia Mourão(vera.mourao@fgv.br) on 2011-05-25T16:55:56Z (GMT) No. of bitstreams: 1 61090100017.pdf: 1173276 bytes, checksum: cda7eb208e82169a3eb90adf64163258 (MD5)
Approved for entry into archive by Vera Lúcia Mourão(vera.mourao@fgv.br) on 2011-05-25T16:58:29Z (GMT) No. of bitstreams: 1 61090100017.pdf: 1173276 bytes, checksum: cda7eb208e82169a3eb90adf64163258 (MD5)
Made available in DSpace on 2011-05-25T17:23:04Z (GMT). No. of bitstreams: 1 61090100017.pdf: 1173276 bytes, checksum: cda7eb208e82169a3eb90adf64163258 (MD5) Previous issue date: 2010-07-07
This thesis aims to evaluate whether humorous television commercials (TVCs) work for non-prescription drugs, known as “over-the-counter” (OTC). The construct humor in advertising is controversial since it involves complex and broad typology, and depends on the audience characteristics. Several studies within different product categories indicated that some consumer goods are better suited for humorous TVCs, while others, such as OTC drugs, may not take advantage from it. Paradoxically, drug announcers spend billions of dollars worldwide in humorous OTC ads. An experiment with real consumers was designed as between-and-within-subjects, to test three hypotheses. Sixty women were exposed to pairs of humorous and non-humorous TVCs, for each of the three drug categories (analgesics, vitamins, and laxatives). We used fictional brand names and real ads, and measured four dependant variables: attitude toward the advertising (AAD), attitude toward the brand (ABR), purchase intention (PI), and brand choice (BC), after subjects being exposed to manipulations of two independent variables: humorous vs. non-humorous TV commercials, for the drug categories. Conditional logit model confirmed that humor does not help to persuade respondents, whose choices, attitudes, and purchase intention were less favorable with humorous TVCs, in comparison to non-humorous executions. Future research is presented regarding marketing for pharmaceutical products.
APA, Harvard, Vancouver, ISO, and other styles
9

Pedrouzo, Lanuza Marta. "Pharmaceuticals and personal care products in environmental waters." Doctoral thesis, Universitat Rovira i Virgili, 2010. http://hdl.handle.net/10803/9058.

Full text
Abstract:
En la presente Tesis Doctoral se han desarrollado diferentes métodos analíticos para la determinación de pharmaceuticals and personal care products (PPCPs) en aguas medioambientales. El término PPCPs engloba todos los fármacos, drogas de abuso, hormonas y los excipientes activos incluidos en productos de uso personal, así como los metabolitos, conjugados y sub-productos de transformación. Los métodos desarrollados han estado basados en extracción en fase sólida o extracción con barras magnéticas agitadoras seguidos de la cromatografía líquida acoplada a la espectrometría de masas o de masas en tándem. Debido a los bajos límites de detección alcanzados, estos métodos se pudieron aplicar a la monitorización de estos compuestos en diferentes plantas depuradoras del área de Tarragona, donde la información al respeto era inexistente. Debido a que el principal destino de las aguas residuales son los ríos, se analizaron aguas del Ter, Llobregat y Ebro. Para completar el estudio, la presencia de PPCPs fue determinada en aguas de consumo.
In the framework of the present Doctoral Thesis different analytical methods have been developed to determine pharmaceuticals and personal care products (PPCPs) in environmental waters. The term PPCPs cover all the pharmaceuticals, drugs of abuse, hormones, the active compounds included in personal care products, and also metabolites, conjugates and transformation sub-products. The developed methods were based on solid-phase extraction and stir bar sorptive extraction followed by liquid chromatography coupled to mass spectrometry and tandem mass spectrometry. Achieving the low limits of detection, these methods could be applied to the monitoring of these compounds in different sewage treatment plants from Tarragona Region, where not data were available. The PPCPs resulting in the effluent sewage waters can achieve rivers. Therefore, waters from three rivers: Ter, Llobregat and Ebro were analyzed. To complete the study, also drinking water was analyzed to determine PPCPs.
APA, Harvard, Vancouver, ISO, and other styles
10

Gibson, Sara Nichols. "Oxidation of pharmaceuticals and personal products by permanganate." Thesis, Georgia Institute of Technology, 2010. http://hdl.handle.net/1853/33870.

Full text
Abstract:
Pharmaceuticals and personal care products (PPCPs) are widely used, resulting in trace amounts being detected in the aquatic environment. This presence is of human health and ecological concern and it is necessary to determine the best methods to eliminate them from our waters. The oxidation of PPCPs by permanganate was evaluated using a spectrophotometer to monitor permanganate reduction. Thirty-nine compounds were chosen to represent numerous classifications, including beta blockers, cephalosporins, fluoroquinolones, macrolides, non-steroidal anti-inflammatory drugs, phenol structures, polypeptides, sulfonamides, tetracyclines, and triazines. The reactivity of each compound was determined by measuring the absorbance of permanganate over time as it reacted with an excess of the compound. The absorbance data was fit to a pseudo-first-order reaction model that accounted for the growth of manganese dioxide colloids. The most reactive groups that reduced permanganate within minutes at pH 7.0 were the cephalosporins, phenol structures, and tetracyclines. The majority of the remaining pharmaceuticals and personal care products were moderately or weakly reactive (reducing permanganate within hours). Caffeine, carbadox, monensin, simetone, and tri(2-carboxyethyl)phosphine were poorly reactive (reducing permanganate over days). Metoprolol was the only selected compound that was determined to be potentially non-reactive (no reaction after 1 day). Polarizability and refractive index of the organic compounds showed significant positive correlations (R-squared > 0.50) with the first-order reaction rates for non-steroidal anti-inflammatory drugs and the phenol structures group. The half-life of each PPCP was determined based on a typical dosage of permanganate used for pre-oxidation. Eleven of the thirty-nine PPCPs had a half-life of less than thirty minutes (a typical contact time), indicating that oxidation by permanganate may be a viable option. There are many opportunities for further research in this area, including investigating more PPCPs, physicochemical property correlations, and the impact of water quality conditions
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pharmaceutical producers"

1

Vaccine nation: A thriller. Las Vegas, NV]: Thomas & Mercer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Institute, Pennsylvania Bar. Pharmaceutical litigation. [Mechanicsburg, Pa.]: Pennsylvania Bar Institute, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fissore, Davide, Roberto Pisano, and Antonello Barresi, eds. Freeze Drying of Pharmaceutical Products. Boca Raton : CRC Press, [2020] | Series: Advances in drying science and technology: CRC Press, 2019. http://dx.doi.org/10.1201/9780429022074.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Canada. Library of Parliament. Research Branch., ed. Patent protection for pharmaceutical products. [Ottawa]: Library of Parliament, Research Branch, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Attaway, David H., and Oskar R. Zaborsky, eds. Pharmaceutical and Bioactive Natural Products. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4899-2391-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schaumann, Leif. Pharmaceutical industry perspectives: Japanese pharmaceutical internationalization. Menlo Park, CA (333 Ravenswood Ave., Menlo Park 94025-3493): SRI International, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Birkinshaw, F. L. Analytical procedures for chiral pharmaceutical products. Manchester: UMIST, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Merkus, Henk G., Gabriel M. H. Meesters, and Wim Oostra, eds. Particles and Nanoparticles in Pharmaceutical Products. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-94174-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pal, Dilipkumar, and Amit Kumar Nayak, eds. Bioactive Natural Products for Pharmaceutical Applications. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-54027-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Canada, Canada Industry. Chemicals, pharmaceuticals and plastics: Forest products. Ottawa, Ont: Industry Canada, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Pharmaceutical producers"

1

Eggersdorfer, Manfred. "Vitamins — Opportunities and Challenges for Both Western and Chinese Producers." In The Chemical and Pharmaceutical Industry in China, 265–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 2005. http://dx.doi.org/10.1007/3-540-26561-9_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Roy, Sudipendra Nath, and Tuhin Sengupta. "Impact of IoT on the Healthcare Producers: Epitomizing Pharmaceutical Drug Discovery Process." In Internet of Things Use Cases for the Healthcare Industry, 127–56. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-37526-3_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lancini, Giancarlo, and Arnold L. Demain. "Bacterial Pharmaceutical Products." In The Prokaryotes, 257–80. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-31331-8_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Demain, Arnold L., and Giancarlo Lancini. "Bacterial Pharmaceutical Products." In The Prokaryotes, 812–33. New York, NY: Springer New York, 2006. http://dx.doi.org/10.1007/0-387-30741-9_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Schaefer, Bernd. "Pharmaceuticals." In Natural Products in the Chemical Industry, 209–518. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-54461-3_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Howard, John, and Elizabeth E. Hood. "The Future of Plant-Produced Pharmaceuticals and Industrial Proteins." In Commercial Plant-Produced Recombinant Protein Products, 261–74. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43836-7_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lipp, Ralph, and Emo Pungor. "Formulation of Biotech Products." In Pharmaceutical Biotechnology, 173–85. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA, 2005. http://dx.doi.org/10.1002/3527602410.ch9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fuchs, Heidi, and Hansjörg Schlegel. "Marketing of Pharmaceutical Products." In Dermatopharmacology of Topical Preparations, 443–54. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-57145-9_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rehman, Qudsia, Muhammad Sajid Hamid Akash, Imran Imran, and Kanwal Rehman. "Stability of Pharmaceutical Products." In Drug Stability and Chemical Kinetics, 147–54. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-6426-0_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ockerman, Herbert W. "Pharmaceutical and Biological Products." In Inedible Meat by-Products, 283–328. Dordrecht: Springer Netherlands, 1992. http://dx.doi.org/10.1007/978-94-011-7933-1_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical producers"

1

Calalb, Tatiana. "MICROALGAE AS BIOTECHNOLOGICAL PRODUCERS OF FOOD, COSMETIC AND PHARMACEUTICAL PRODUCTS." In XIth International Congress of Geneticists and Breeders from the Republic of Moldova. Scientific Association of Geneticists and Breeders of the Republic of Moldova, Institute of Genetics, Physiology and Plant Protection, Moldova State University, 2021. http://dx.doi.org/10.53040/cga11.2021.117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hada, Izabela Diana. "Analysis and Evolution of Profitability in the Pharmaceutical Field in Romania." In International Conference Innovative Business Management & Global Entrepreneurship. LUMEN Publishing, 2020. http://dx.doi.org/10.18662/lumproc/ibmage2020/55.

Full text
Abstract:
The pharmaceutical industry is an important field of activity that contributes to the diagnosis, treatment, maintenance of the health of the population. The need of pharmaceuticals has led to an increase in both the number of drug manufacturers and the number of distributors. A significant part of the specialized studies deals with the problem of the profitability of the pharmaceutical industry. The study of the financial performance of the economic entities in the pharmaceutical field in Romania is a necessary concern in the conditions of a progressive annual increase of the profitability of this sector. The main purpose of this paper is the analysis and presentation of the evolution of profitability indicators (return on assets, return on capital, return on sales) as part of the activity of assessing the financial performance of economic entities operating in Romania in the pharmaceutical industry (manufacturing of basic pharmaceutical products - CAEN code 2110). Profitability indicators were analyzed for a number of 46 entities in the pharmaceutical industry in Romania for a period of 20 years (1999-2018). We are talking in this case about a turnover of 1.1 Billion lei (249.2 million euros), a number of employees of 3,098 employees, a profit of 135.2 million lei (30.7 million euros) - representing 0.12% of the net profit made in Romania. The research results show that in the period 2008-2009, the financial crisis left a strong mark on the evolution of profitability in the pharmaceutical industry. However, during the 20 years we talk about a positive evolution, in the sense of increasing the profitability of this field, which justifies the increase in the consumption of pharmaceuticals products.
APA, Harvard, Vancouver, ISO, and other styles
3

Bhushan, Indu. "Efficient media for high production of microbial lipase from Bacillus subtilis (BSK-L) using response surface methodology for enantiopure synthesis of drug molecules." In 2nd International Scientific Conference "Plants and Microbes: the Future of Biotechnology". PLAMIC2020 Organizing committee, 2020. http://dx.doi.org/10.28983/plamic2020.044.

Full text
Abstract:
Lipases are a multipurpose enzyme that holds a significant position in industrial applications due to its ability to catalyse a large number of reactions such as hydrolysis, esterification, interesterification, transesterification which makes it a potential candidate. It is also used for the separation of chiral drugs from the racemic mixture and this property of lipase is considered very important in pharmaceutical industries for the synthesis of enantiopure bioactive molecules. Assuming the tremendous importance of lipases, as stereoselective biocatalysts, in pharmaceuticals and various other commercial applications, industrial enzymologists have been forced to search for those microorganisms which are able to produce novel biocatalysts at reasonably high yield. In the present study microbial lipase was isolated from the water sample of pond at Katra, Jammu and Kashmir (India). This enzyme has shown wide specificity and higher enantioselectivity, which make it pharmaceutical important enzyme. To make it economical for industrial application, it was produced on cheap nutrient media using Response Surface Methodology and got maximum production. It was used for resolution of chiral drugs and the significant results obtained during the course of work shall have potential towards pharmaceutical industries.
APA, Harvard, Vancouver, ISO, and other styles
4

Arpagaus, Cordin. "Nano spray drying of pharmaceuticals." In 21st International Drying Symposium. Valencia: Universitat Politècnica València, 2018. http://dx.doi.org/10.4995/ids2018.2018.7356.

Full text
Abstract:
Spray drying plays a crucial role in the processing of pharmaceutical products such as pills, capsules, and tablets as it is used to convert drug containing liquids into dried powdered forms. Nano spray drying is in particular used to improve drug formulation by encapsulating active ingredients in polymeric wall materials for protection and delivering the drugs to the right place and time in the body. The nano spray dryer developed in the recent years extends the spectrum of produced powder particles to the submicron- and nanoscale with very narrow size distributions and sample quantities in the milligram scale at high product yields. This enables the economical use of expensive active pharmaceutical ingredients and pure drugs. The present paper explains the concept of nano spray drying and discusses the influence of the main process parameters on the final powder properties like particle size, morphology, encapsulation efficiency, and drug loading. Application results of nano spray drying for the formulation and encapsulation of different drugs are reviewed. Keywords: nano spray drying; pharmaceuticals; drug encapsulation; particle size; powder
APA, Harvard, Vancouver, ISO, and other styles
5

Ahmed S. Hussein, Mai, Mohamed Attia, and Noha Mohamed. "Child-resistant features of pharmaceutical packaging in the egyptian and global market; a comparative study." In 10th International Symposium on Graphic Engineering and Design. University of Novi Sad, Faculty of technical sciences, Department of graphic engineering and design,, 2020. http://dx.doi.org/10.24867/grid-2020-p39.

Full text
Abstract:
Child-Resistant packaging is substantial requirement especially when it is related to pharmaceuticals. Children under five years old are the most groups in risk of drug poisoning, as a result of their constant passion and attracting their attention to medicines, especially the distinctive color and small size. Due to the presence of medicines for adults, especially chronic diseases that require the presence of the drug always at home with exciting properties for the passion of a young child who is affected by colors and the small size which they can insert easily into their mouths. The child-resistant features attached to packages may present a problem (e.g., how to open the package) to its potential user (child or adult). Many of these features are used with the primary packaging and less for the secondary ones. Are these features efficient with available cost or not. Evaluation of each one might be varied according to package structure, level and child behavior. Therefore, the importance of adding some features in the pharmaceutical packaging Child-Resistant, in order to achieve the safety of children with a targeted age (children under 5 years old). By adding these special properties to the pharmaceutical packaging it will affect the design of the pharmaceutical packaging. Finally, this paper aimed to review and evaluate the child resistant features & securing methods that are used with pharmaceutical products in the Egyptian market, with which are available globally, then make a comparison between them by description and analysis.
APA, Harvard, Vancouver, ISO, and other styles
6

Deckers, Jan. "Treatment of Low-Level Radioactive Waste by Plasma: A Proven Technology?" In ASME 2010 13th International Conference on Environmental Remediation and Radioactive Waste Management. ASMEDC, 2010. http://dx.doi.org/10.1115/icem2010-40299.

Full text
Abstract:
Large amounts of actual and historical low level radioactive waste, with varying characteristics, are stored and generated from the operation and maintenance of nuclear power plants, the nuclear fuel cycle, research laboratories, pharmaceutical and medical facilities. Virtual all of these waste streams can be treated by the plasma technology resulting in a final product free of organics, liquids and moisture, and meeting without a doubt the acceptance criteria for safe storage and disposal. The plasma is a highly desirable heat source. Its high temperature of up to 10.000 °C can treat the radioactive waste as is. The inorganic materials are melted into a glassy slag, containing most of the radioactive isotopes, while the organic material is vaporized into a syngas and subsequently oxidized in an afterburner. This technology is very suitable for historical waste containing mixtures of inorganic, organic, liquids, sludge, etc, with almost no waste preparation and with minimal risk for radioactive contamination and exposure. Plasma technology offers a high volume waste reduction factor (VRF) that minimizes the volume and overall costs of waste storage and disposal. In addition, as plasma technology can recondition previously conditioned waste packages that no longer meet the present acceptance criteria for final disposal, it offers a solution to the growing demand for improved quality of final waste forms. As such, plasma technology is of great value, not just to waste producers but to future generations as well. This paper describes further the principles of plasma, the different waste feed systems, off-gas treatment, operational experience and future plasma plants.
APA, Harvard, Vancouver, ISO, and other styles
7

Lewis, Neil. "Microspectroscopic imaging of pharmaceutical products." In Biomedical Topical Meeting. Washington, D.C.: OSA, 2004. http://dx.doi.org/10.1364/bio.2004.tha5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sandhu, Jaspal S., Aman Bhandari, Mahad Ibrahim, and P. Balakrishnan. "Appropriate Design of Medical Technologies for Emerging Regions: The Case of Aurolab." In ASME 2005 International Mechanical Engineering Congress and Exposition. ASMEDC, 2005. http://dx.doi.org/10.1115/imece2005-81291.

Full text
Abstract:
Healthcare delivery in emerging regions presents a unique set of challenges and is characterized largely by poor infrastructure. Though there is significant variation from country to country - and even within countries - in emerging regions, common themes emerge, such as overreliance on direct payment schemes, unreliable supply chains, and intermittent power in rural settings. These themes in turn impose particular design requirements on manufacturers of medical devices and pharmaceuticals; this paper focuses on these design requirements. We illustrate the importance of designing specifically for the developing context, using the example of Aurolab, a non-profit medical manufacturer located in Tamil Nadu, India. Started in 1992, Aurolab began operations with the manufacture of intraocular lenses (IOL), implantable polymer lenses for cataract surgery, becoming the first to produce this technology in India. Today Aurolab produces a variety of medical devices and ophthalmic pharmaceuticals, and deliver their products to 120 countries worldwide. Aurolab’s products illustrate many of the key design requirements for healthcare delivery in India and in other emerging contexts.
APA, Harvard, Vancouver, ISO, and other styles
9

Kamijo, Koichi. "Future Sales Estimation using Patents." In 9th International Conference on Computational Science and Engineering (CSE 2021). Academy and Industry Research Collaboration Center (AIRCC), 2021. http://dx.doi.org/10.5121/csit.2021.112404.

Full text
Abstract:
We propose a model to improve estimation accuracy of the future sales volume, focusing on pharmaceutical products, from their patents. Our approach is based on an analysis of patents obtained in the early development stages of the products. The development of pharmaceuticals often takes a long time (up to several decades in some cases), and the costs are huge, even exceeding one billion USD for just one product. Therefore, it is strongly desirable to estimate future sales volume at an early stage. One piece of information potentially useful for the estimation is the brand, i.e., the name of the developing company. Our model learns the sales volume and words used in multiple patent specifications and also focuses on the extent to which “seasonal” words are used. Experiments showed that our model much improved the accurately of the sales volume estimation compared with the case of just estimating from its brand name.
APA, Harvard, Vancouver, ISO, and other styles
10

Kesic, Dragan. "Significance of products for pharmaceutical companies." In The 6th International Virtual Scientific Conference. Publishing Society, 2017. http://dx.doi.org/10.18638/ictic.2017.6.1.310.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pharmaceutical producers"

1

Seuba, Xavier. Free Trade of Pharmaceutical Products. Geneva, Switzerland: International Centre for Trade and Sustainable Development, 2010. http://dx.doi.org/10.7215/ip_ip_20100426.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lubowa, Nasser, Zita Ekeocha, Stephen Robert Byrn, and Kari L. Clase. Pharmaceutical Industry in Uganda: A Review of the Common GMP Non-conformances during Regulatory Inspections. Purdue University, December 2021. http://dx.doi.org/10.5703/1288284317442.

Full text
Abstract:
The prevalence of substandard medicines in Africa is high but not well documented. Low and Middle-Income Countries (LMICs) are likely to face considerable challenges with substandard medications. Africa faces inadequate drug regulatory practices, and in general, compliance with Good Manufacturing Practices (GMP) in most of the pharmaceutical industries is lacking. The majority of pharmaceutical manufacturers in developing countries are often overwhelmed by the GMP requirements and therefore are unable to operate in line with internationally acceptable standards. Non-conformances observed during regulatory inspections provide the status of the compliance to GMP requirements. The study aimed to identify the GMP non-conformances during regulatory inspections and gaps in the production of pharmaceuticals locally manufactured in Uganda by review of the available 50 GMP reports of 21 local pharmaceutical companies in Uganda from 2016. The binary logistic generalized estimating equations (GEE) model was applied to estimate the association between odds of a company failing to comply with the GMP requirements and non-conformances under each GMP inspection parameter. Analysis using dummy estimation to linear regression included determination of the relationship that existed between the selected variables (GMP inspection parameters) and the production capacity of the local pharmaceutical industry. Oral liquids, external liquid preparations, powders, creams, and ointments were the main categories of products manufactured locally. The results indicated that 86% of the non-conformances were major, 11% were minor, and 3% critical. The majority of the non-conformances were related to production (30.1%), documentation (24.5%), and quality control (17.6%). Regression results indicated that for every non-conformance under premises, equipment, and utilities, there was a 7-fold likelihood of the manufacturer failing to comply with the GMP standards (aOR=6.81, P=0.001). The results showed that major non-conformances were significantly higher in industries of small scale (B=6.77, P=0.02) and medium scale (B=8.40, P=0.04), as compared to those of large scale. This study highlights the failures in quality assurance systems and stagnated GMP improvements in these industries that need to be addressed by the manufacturers with support from the regulator. The addition of risk assessment to critical production and quality control operations and establishment of appropriate corrective and preventive actions as part of quality management systems are required to ensure that quality pharmaceuticals are manufactured locally.
APA, Harvard, Vancouver, ISO, and other styles
3

Berndt, Ernst, Zvi Griliches, and Joshua Rosett. Auditing the Producer Price Index: Micro Evidence From Prescription Pharmaceutical Preparations. Cambridge, MA: National Bureau of Economic Research, March 1992. http://dx.doi.org/10.3386/w4009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Helland, Eric, Darius Lakdawalla, Anup Malani, and Seth Seabury. Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market. Cambridge, MA: National Bureau of Economic Research, March 2014. http://dx.doi.org/10.3386/w20005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Barefoot, Susan F., Bonita A. Glatz, Nathan Gollop, and Thomas A. Hughes. Bacteriocin Markers for Propionibacteria Gene Transfer Systems. United States Department of Agriculture, June 2000. http://dx.doi.org/10.32747/2000.7573993.bard.

Full text
Abstract:
The antibotulinal baceriocins, propionicin PLG-1 and jenseniin G., were the first to be identified, purified and characterized for the dairy propionibaceria and are produced by Propionibacterium thoenii P127 and P. thoenii/jensenii P126, respectively. Objectives of this project were to (a) produce polyclonal antibodies for detection, comparison and monitoring of propionicin PLG-1; (b) identify, clone and characterize the propionicin PLG-1 (plg-1) and jenseniin G (jnG) genes; and (3) develop gene transfer systems for dairy propionibacteria using them as models. Polyclonal antibodies for detection, comparison and monitoring of propionicin PLG-1 were produced in rabbits. Anti-PLG-1 antiserum had high titers (256,000 to 512,000), neutralized PLG-1 activity, and detected purified PLG-1 at 0.10 mg/ml (indirect ELISA) and 0.033 mg/ml (competitive indirect ELISA). Thirty-nine of 158 strains (most P. thoenii or P. jensenii) yielded cross-reacting material; four strains of P. thoenii, including two previously unidentified bacteriocin producers, showed biological activity. Eight propionicin-negative P127 mutants produced neither ELISA response nor biological activity. Western blot analyses of supernates detected a PLG-1 band at 9.1 kDa and two additional protein bands with apparent molecular weights of 16.2 and 27.5 kDa. PLG-1 polyclonal antibodies were used for detection of jenseniin G. PLG-1 antibodies neutralized jenseniin G activity and detected a jenseniin G-sized, 3.5 kDa peptide. Preliminary immunoprecipitation of crude preparations with PLG-1 antibodies yielded three proteins including an active 3-4 kDa band. Propionicin PLG-1 antibodies were used to screen a P. jensenii/thoenii P126 genomic expression library. Complete sequencing of a cloned insert identified by PLG-1 antibodies revealed a putative response regulator, transport protein, transmembrane protein and an open reading frame (ORF) potentially encoding jenseniin G. PCR cloning of the putative plg-1 gene yielded a 1,100 bp fragment with a 355 bp ORF encoding 118 amino acids; the deduced N-terminus was similar to the known PLG-1 N-terminus. The 118 amino acid sequence deduced from the putative plg-1 gene was larger than PLG-1 possibly due to post-translational processing. The product of the putative plg-1 gene had a calculated molecular weight of 12.8 kDa, a pI of 11.7, 14 negatively charged residues (Asp+Glu) and 24 positively charged residues (Arg+Lys). The putative plg-1 gene was expressed as an inducible fusion protein with a six-histidine residue tag. Metal affinity chromatography of the fused protein yielded a homogeneous product. The fused purified protein sequence matched the deduced putative plg-1 gene sequence. The data preliminarily suggest that both the plg-1 and jnG genes have been identified and cloned. Demonstrating that antibodies can be produced for propionicin PLG-1 and that those antibodies can be used to detect, monitor and compare activity throughout growth and purification was an important step towards monitoring PLG-1 concentrations in food systems. The unexpected but fortunate cross-reactivity of PLG-1 antibodies with jenseniin G led to selective recovery of jenseniin G by immunoprecipitation. Further refinement of this separation technique could lead to powerful affinity methods for rapid, specific separation of the two bacteriocins and thus facilitate their availability for industrial or pharmaceutical uses. Preliminary identification of genes encoding the two dairy propionibacteria bacteriocins must be confirmed; further analysis will provide means for understanding how they work, for increasing their production and for manipulating the peptides to increase their target species. Further development of these systems would contribute to basic knowledge about dairy propionibacteria and has potential for improving other industrially significant characteristics.
APA, Harvard, Vancouver, ISO, and other styles
6

Huber, Sandra, Mikael Remberger, Arntraut Goetsch, Kirsten Davanger, Lennart Kaj, Dorte Herzke, Martin Schlabach, et al. Pharmaceuticals and additives in personal care products as environmental pollutants. Nordic Council of Ministers, August 2013. http://dx.doi.org/10.6027/tn2013-541.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Munhuweyi, Ngonidzashe Portia, Zita Ekeocha, Stephen Robert Byrn, and Kari L. Clase. Resource Modelling for the QC Laboratory at XYZ Pharmaceuticals in Southern Africa. Purdue University, November 2021. http://dx.doi.org/10.5703/1288284317431.

Full text
Abstract:
Quality control (QC) laboratories are critical components in drug manufacturing and running them efficiently contributes to better, consistent supply of cost-effective quality products, while also and preventing deaths due to untimely delivery or unavailability of medicines. Having a resource modelling tool to estimate resources needed to handle a particular demand in a given system is essential for efficient running of QC laboratory. This study was done to establish such a model at XYZ Pharmaceuticals. The list of all products manufactured by XYZ Pharmaceuticals Southern Africa was reviewed; and product families for all products were identified. Analysts’ hands on time (HOT) to process one sample of each of the product families was estimated. The number of analysts required to support the workload at XYZ Pharmaceuticals was calculated using the HOTs for the different product families and the Maslaton’s Calculation Model. A baseline resource model was established.
APA, Harvard, Vancouver, ISO, and other styles
8

Berndt, Ernst, Zvi Griliches, and Joshua Rosett. On the Accuracy of Producer Price Indexes for Pharmaceutical Preparations: An Audit Based on Detailed Firm-Specific Data. Cambridge, MA: National Bureau of Economic Research, October 1990. http://dx.doi.org/10.3386/w3490.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Agu, Monica, Zita Ekeocha, Stephen Robert Byrn, and Kari L. Clase. The Impact of Mentoring as a GMP Capability Building Tool in The Pharmaceutical Manufacturing Industry in Nigeria. Purdue University, December 2012. http://dx.doi.org/10.5703/1288284317447.

Full text
Abstract:
Good Manufacturing Practices (GMP), a component of Pharmaceutical Quality Systems, is aimed primarily at managing and minimizing the risks inherent in pharmaceutical manufacture to ensure the quality, safety and efficacy of products. Provision of adequate number of personnel with the necessary qualifications/practical experience and their continuous training and evaluation of effectiveness of the training is the responsibility of the manufacturer. (World Health Organization [WHO], 2014; International Organization for Standardization [ISO], 2015). The classroom method of training that has been used for GMP capacity building in the pharmaceutical manufacturing industry in Nigeria over the years, delivered by experts from stringently regulated markets, have not yielded commensurate improvement in the Quality Management Systems (QMS) in the industry. It is necessary and long over-due to explore an alternative training method that has a track record of success in other sectors. A lot of studies carried out on mentoring as a development tool in several fields such as academia, medicine, business, research etc., reported positive outcomes. The aim of this study was to explore mentoring as an alternative GMP training method in the pharmaceutical manufacturing industry in Nigeria. Specifically, the aim of this study was to evaluate the impact of mentoring as a GMP capability building tool in the pharmaceutical manufacturing industry in Nigeria, with focus on GMP documentations in XYZ pharmaceutical manufacturing company located in South-Western region of Nigeria. The methodology comprised gap assessment of GMP documentation of XYZ company to generate current state data, development of training materials based on the identified gaps and use of the training materials for the mentoring sessions. The outcome of the study was outstanding as gap assessment identified the areas of need that enabled development efforts to be targeted at these areas, unlike generic classroom training. The mentees’ acceptance of the mentoring support was evident by their request for additional training in some other areas related to the microbiology operations that were not covered in the gap assessment. This result portrays mentoring as a promising tool for GMP capacity building, but more structured studies need to be conducted in this area to generate results that can be generalized.
APA, Harvard, Vancouver, ISO, and other styles
10

Doddridge, Gregory, Steven Doherty, Zhenqi Shi, Ting-Kuo Huang, Nina Cauchon, Tony Wang, Orna Wisniak, Clarice Hutchens, and Isabelle Lequeux. Regulatory submission & lifecycle management strategy of models used in the manufacture of pharmaceutical and biological products. BioPhorum, January 2021. http://dx.doi.org/10.46220/2020reg002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical producers' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography